Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas, and may be useful for the study of breast and ovarian cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 165.00 | |
5 mg | In stock | $ 413.00 | |
10 mg | In stock | $ 689.00 | |
25 mg | In stock | $ 1,490.00 |
Description | Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas, and may be useful for the study of breast and ovarian cancer. |
Targets&IC50 | FAK:1 nM, FER:900 nM, FES:1040 nM |
In vitro | 4T1, Py2T, and Py2T-LT cells were exposed to increasing concentrations of BI-853520 (0, 0.1, 0.5, 1, 5, and 10 μM for 4T1 cells; 1, 3, and 10 μM for Py2T and Py2T-LT cells) for 24 hours. The results demonstrate that BI-853520 reduces Y397-FAK phosphorylation in a dose-dependent and time-dependent manner[2]. |
In vivo | In PC-3 cells, BI-853520(Ifebemtinib;0-3 μM; 2 h) resulted in a concentration-dependent reduction of the signal, with a median EC50 value of 1 nM[2]. |
Synonyms | IN-10018, BI-853520 |
Molecular Weight | 588.55 |
Formula | C28H28F4N6O4 |
CAS No. | 1227948-82-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (84.89 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ifebemtinib 1227948-82-4 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors FAK IN-10018 BI-853520 inhibitor inhibit